Quantum Biopharma Ltd. Annual Report: A Plain-English Guide

I’ve put together this guide to help you understand how Quantum Biopharma performed this year. My goal is to cut through the corporate jargon so you can decide if this company fits your investment goals.

1. What does this company do?

Quantum Biopharma is a Canadian biotech firm focused on developing new drugs and functional beverages. They operate through two main branches: Lucid Psycheceuticals, which researches treatments for brain diseases, and FSD Biosciences, which manages their drug development pipeline.

Important Note: In August 2024, the company completed a 65-for-1 reverse stock split. This action was taken to meet the Nasdaq’s $1.00 minimum bid price requirement, as the stock had previously traded as a "penny stock" under $0.10.

2. Financial performance

In 2025, Quantum Biopharma reported a loss of approximately $14.2 million, reflecting the high costs associated with early-stage drug development. Because the company is in the research phase, annual revenue remains minimal, totaling less than $100,000. The company reports in U.S. dollars; consequently, the weakening of the Canadian dollar against the U.S. dollar increased the reported cost of their Canadian-based research operations.

3. Major projects

The company is currently prioritizing two primary initiatives:

• Lucid-MS: A drug candidate for multiple sclerosis. The company is finalizing data to support an application for human trials, with the goal of initiating Phase 2 trials by late 2025 or early 2026.
• Unbuzzd™: A functional beverage designed to assist the body in processing alcohol. The company has shifted to a licensing model with distributors to reduce overhead costs while expanding retail availability.

4. Financial health

The company is not currently profitable and expects to continue incurring losses. With a monthly burn rate of $800,000 to $1 million, their current cash reserves are expected to last less than 12 months. To complete their planned Phase 2 trials, the company will need to raise additional capital, likely through the issuance of new shares. Investors should be aware that such offerings would dilute existing ownership percentages.

5. Key risks

Investing in this company involves significant risk. Key factors to consider include:

• Research Uncertainty: The company’s value is tied to the success of its drug trials. If these trials fail, the company’s primary assets may lose their value entirely.
• Regulatory Hurdles: All drug development is subject to strict oversight by the FDA and Health Canada. Any safety concerns or regulatory delays could halt operations and exhaust remaining cash.
• Operational Dependency: The company relies on third-party research organizations to conduct its trials. Delays or failures by these partners will directly impact the company’s development timelines.
• Legal & Structural Factors: As a Canadian-based entity, legal enforcement for U.S. investors can be more complex. Additionally, insiders hold special classes of shares that provide them with greater voting power than the average shareholder.
• Cryptocurrency Holdings: The company maintains 5-8% of its cash reserves in Bitcoin. This introduces price volatility that is unrelated to the core pharmaceutical business.

6. Future outlook

The company’s long-term goal is to advance its research to a point where it becomes an attractive acquisition target for a larger pharmaceutical firm. Success is entirely dependent on transitioning from lab research to successful human trials over the next 18 months. Given the competitive nature of the biotech industry, investors should weigh the potential for a buyout against the company's immediate need for further funding and the inherent risks of drug development.